VIRX - Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment
- Viracta Therapeutics ( NASDAQ: VIRX ) on Wednesday said the European Commission had granted an orphan drug designation to its all-oral combination product candidate Nana-val for the treatment of peripheral T-cell lymphoma.
- The company said this was its first such designation granted in Europe and the fifth globally.
- Nana-val is a combination of the company's inhibitor nanatinostat and antiviral agent valganciclovir.
- The U.S. FDA had previously granted Nana-val an orphan drug designation for the treatment of T-cell lymphoma and a few other indications, VIRX said.
- The orphan drug designation by the European Commission was based on a positive opinion given by the European drug regulator's human medicines committee.
- VIRX stock -4.9% to $4.09 in early trading.
For further details see:
Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment